Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo.

Yasukawa M, Fujihara H, Fujimori H, Kawaguchi K, Yamada H, Nakayama R, Yamamoto N, Kishi Y, Hamada Y, Masutani M.

Int J Mol Sci. 2016 Feb 24;17(3):272. doi: 10.3390/ijms17030272.

2.

Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.

Sui H, Shi C, Yan Z, Li H.

Drug Des Devel Ther. 2015 Jun 22;9:3183-90. doi: 10.2147/DDDT.S82035. eCollection 2015.

3.

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.

Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J.

Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84. doi: 10.1073/pnas.0806092105. Epub 2008 Oct 29.

4.

Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.

Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PW, Holstege H, Liu X, van Drunen E, Beverloo HB, Smith GC, Martin NM, Lau A, O'Connor MJ, Jonkers J.

Clin Cancer Res. 2008 Jun 15;14(12):3916-25. doi: 10.1158/1078-0432.CCR-07-4953.

5.

Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells.

Minami D, Takigawa N, Takeda H, Takata M, Ochi N, Ichihara E, Hisamoto A, Hotta K, Tanimoto M, Kiura K.

Mol Cancer Res. 2013 Feb;11(2):140-8. doi: 10.1158/1541-7786.MCR-12-0401. Epub 2012 Dec 13.

6.

Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.

Kortmann U, McAlpine JN, Xue H, Guan J, Ha G, Tully S, Shafait S, Lau A, Cranston AN, O'Connor MJ, Huntsman DG, Wang Y, Gilks CB.

Clin Cancer Res. 2011 Feb 15;17(4):783-91. doi: 10.1158/1078-0432.CCR-10-1382. Epub 2010 Nov 19.

7.

Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.

Ivy SP, Liu JF, Lee JM, Matulonis UA, Kohn EC.

Expert Opin Investig Drugs. 2016;25(5):597-611. doi: 10.1517/13543784.2016.1156857. Epub 2016 Mar 16. Review.

PMID:
26899229
8.

Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.

Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, Pommier Y.

J Pharmacol Exp Ther. 2014 Jun;349(3):408-16. doi: 10.1124/jpet.113.210146. Epub 2014 Mar 20.

9.

Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.

Gunderson CC, Moore KN.

Future Oncol. 2015;11(5):747-57. doi: 10.2217/fon.14.313. Review.

PMID:
25757679
10.

Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors.

Norris RE, Adamson PC, Nguyen VT, Fox E.

Pediatr Blood Cancer. 2014 Jan;61(1):145-50. doi: 10.1002/pbc.24697. Epub 2013 Sep 4.

11.

Novel poly (ADP-ribose) polymerase inhibitor, AZD2281, enhances radiosensitivity of both normoxic and hypoxic esophageal squamous cancer cells.

Zhan L, Qin Q, Lu J, Liu J, Zhu H, Yang X, Zhang C, Xu L, Liu Z, Cai J, Ma J, Dai S, Tao G, Cheng H, Sun X.

Dis Esophagus. 2016 Apr;29(3):215-23. doi: 10.1111/dote.12299. Epub 2015 Jan 21.

PMID:
25604309
12.

Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.

van de Ven M, van der Burg E, van der Gulden H, Klarenbeek S, Bouwman P, Jonkers J.

J Pathol. 2017 Mar;241(4):511-521. doi: 10.1002/path.4857. Epub 2017 Jan 23.

PMID:
27943283
13.

Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor.

Kivlin CM, Watson KL, Al Sannaa GA, Belousov R, Ingram DR, Huang KL, May CD, Bolshakov S, Landers SM, Kalam AA, Slopis JM, McCutcheon IE, Pollock RE, Lev D, Lazar AJ, Torres KE.

Cancer Biol Ther. 2016;17(2):129-38. doi: 10.1080/15384047.2015.1108486. Epub 2015 Dec 9.

14.

Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.

Hijaz M, Chhina J, Mert I, Taylor M, Dar S, Al-Wahab Z, Ali-Fehmi R, Buekers T, Munkarah AR, Rattan R.

Gynecol Oncol. 2016 Aug;142(2):323-31. doi: 10.1016/j.ygyno.2016.06.005. Epub 2016 Jun 16.

PMID:
27282964
15.

Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.

Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, Chen K, Mezzanzanica D, Xue F, Sood AK, Zhang W.

J Natl Cancer Inst. 2015 May 20;107(7). pii: djv108. doi: 10.1093/jnci/djv108. Print 2015 Jul. Erratum in: J Natl Cancer Inst. 2017 Nov 1;109(11):.

16.

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.

Samol J, Ranson M, Scott E, Macpherson E, Carmichael J, Thomas A, Cassidy J.

Invest New Drugs. 2012 Aug;30(4):1493-500. doi: 10.1007/s10637-011-9682-9. Epub 2011 May 18.

PMID:
21590367
17.

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A.

Lancet Oncol. 2011 Sep;12(9):852-61. doi: 10.1016/S1470-2045(11)70214-5. Epub 2011 Aug 19.

PMID:
21862407
18.

PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells.

Huang SH, Xiong M, Chen XP, Xiao ZY, Zhao YF, Huang ZY.

Oncol Rep. 2008 Sep;20(3):567-72.

PMID:
18695907
19.

Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.

Jang NY, Kim DH, Cho BJ, Choi EJ, Lee JS, Wu HG, Chie EK, Kim IA.

BMC Cancer. 2015 Mar 3;15:89. doi: 10.1186/s12885-015-1090-7.

20.

The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.

Miller RE, Ledermann JA.

Clin Adv Hematol Oncol. 2016 Aug;14(8):619-27. Review.

PMID:
27487106

Supplemental Content

Support Center